Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
Risk & Volatility
Capricor Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Institutional & Insider Ownership
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Capricor Therapeutics and BioCardia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -56.60% | -43.97% |
| BioCardia | N/A | -569.36% | -183.15% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Capricor Therapeutics and BioCardia, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
Capricor Therapeutics presently has a consensus target price of $30.25, suggesting a potential upside of 241.04%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,587.59%. Given BioCardia’s higher possible upside, analysts clearly believe BioCardia is more favorable than Capricor Therapeutics.
Valuation & Earnings
This table compares Capricor Therapeutics and BioCardia”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | N/A | N/A | -$105.04 million | ($2.45) | -3.62 |
| BioCardia | $60,000.00 | 234.72 | -$8.23 million | ($0.64) | -1.45 |
BioCardia has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.
About BioCardia
BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy. BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
